#ASCO14 - Poster: Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer previously treated with docetaxel

CHICAGO, IL USA (UroToday.com) - Presented by Anthony M. Joshua,¹ Neal Shore,² Fred Saad,³ Kim N. Chi,⁴ Carl A. Olsson,⁵ Urban Emmenegger,⁶ Mark Scholz,⁷ William Berry,⁸ Som D. Mukherjee,⁹ Eric Winquist,¹⁰ Naomi B. Haas,¹¹ Nahla Hasabou,¹² Carl Dmuchowski,¹² Frank Perabo,¹² Mohammad Hirmand,¹³ Margaret A. Foley,¹² and Dana Rathkopf,¹⁴ for The Enzalutamide Expanded Access Study Investigators at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting - May 30 - June 3, 2014 - Chicago, Illinois USA

¹University Health Network/Princess Margaret Cancer Centre, Toronto, ON, Canada
²Carolina Urologic Research Center, Myrtle Beach, SC, USA
³University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
⁴British Columbia Cancer Agency–Vancouver Cancer Centre, Vancouver, BC, Canada
⁵Columbia University Medical Center and Integrated Medical Professionals, New York, NY, USA
⁶Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
⁷Prostate Oncology Specialists Inc., Marina del Rey, CA, USA
⁸US Oncology Inc., Cancer Centers of North Carolina, Raleigh, NC, USA
⁹Juravinski Cancer Centre, Hamilton, ON, Canada
¹⁰Western University–London Health Sciences Centre, London, ON, Canada
¹¹Abramson Cancer Center, Philadelphia, PA, USA
¹²Astellas Pharma Global Development, Northbrook, IL, USA
¹³Medivation Inc., San Francisco, CA, USA
¹⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA